PERFORM Publications

Keyword search (4,164 papers available)

Title		Authors	PubMed ID
1	Energy Measures as Biomarkers of SARS-CoV-2 Variants and Receptors	Ghannoum Al Chawaf K; Lahmiri S;	41596038 JMSB
2	Emerging hazardous chemicals and biological pollutants in Canadian aquatic systems and remediation approaches: A comprehensive status report	Adeola AO; Paramo L; Fuoco G; Naccache R;	39278485 CHEMBIOCHEM
3	Insomnia symptoms among older adults during the first year of the COVID-19 pandemic: A longitudinal study	Gong K; Garneau J; Grenier S; Vasiliadis HM; Dang-Vu TT; Dialahy IZ; Gouin JP;	37380593 HKAP
4	Two Chemical Engineers Look at the COVID-19 Pandemic	De Visscher A; Pinheiro Patrício PC;	35942051 ENCS
5	Evaluating SARS-CoV-2 airborne quanta transmission and exposure risk in a mechanically ventilated multizone office building	Yan S; Wang LL; Birnkrant MJ; Zhai J; Miller SL;	35602249 ENCS
6	Predicted coronavirus Nsp5 protease cleavage sites in the human proteome	Scott BM; Lacasse V; Blom DG; Tonner PD; Blom NS;	35379171 ENCS
7	COVID-19-Related Concerns and Symptoms of Anxiety: Does Concern Play a Role in Predicting Severity and Risk?	Benzouak T; Gunpat S; Briner EL; Thake J; Kisely S; Rao S;	34987892 PSYCHOLOGY
8	Removal of SARS-CoV-2 using UV+Filter in built environment: simulation/evaluation by utilizing validated numerical method	Feng Z; Cao SJ; Haghighat F;	34367884 ENCS
9	Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19	Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH;	34209188 CHEMBIOCHEM
10	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2	Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S;	34067878 PHYSICS
11	Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights	Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ;	34021862 CHEMBIOCHEM
12	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection	Safiabadi Tali SH; LeBlanc JJ; Sadiq Z; Oyewunmi OD; Camargo C; Nikpour B; Armanfard N; Sagan SM; Jahanshahi-Anbuhi S;	33980687 IMAGING
13	Indoor airborne disinfection with electrostatic disinfector (ESD): Numerical simulations of ESD performance and reduction of computing time	Feng Z; Cao SJ; Wang J; Kumar P; Haghighat F;	33994653 ENCS
14	Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches	Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ;	33968364 CERMM
15	Identifying and addressing psychosocial determinants of adherence to physical distancing guidance during the COVID-19 pandemic - project protocol.	Durand H, Bacon SL, Byrne M, Kenny E, Lavoie KL, McGuire BE, Mc Sharry J, Meade O, Mooney R, Noone C, O'Connor LL, O'Flaherty K, Molloy GJ	33490860 HKAP
16	Designing a hybrid reinforcement learning based algorithm with application in prediction of the COVID-19 pandemic in Quebec.	Khalilpourazari S, Hashemi Doulabi H	33424076 ENCS
17	The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses.	De Visscher A	32836820 ENCS

Title:	Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights
Authors:	Selvaraj G, Kaliamurthi S, Peslherbe GH, Wei DQ
Link:	https://pubmed.ncbi.nlm.nih.gov/34021862/
DOI:	10.1007/s12539-021-00438-3
Publication:	Interdisciplinary sciences, computational life sciences
Keywords:	Anaphylaxis; Antibody; BNT162b2; COVID-19; IgE; MRNA vaccine; MRNA-1273; PEG; SARS-CoV-2;
PMID:	34021862	Category:	Date Added:	2021-05-22
Dept Affiliation:	CHEMBIOCHEM 1 Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrooke Street W, Montreal, QC, H4B1R6, Canada. gurudeeban.selvaraj@concordia.ca. 2 Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrooke Street W, Montreal, QC, H4B1R6, Canada. 3 The State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang, Shanghai, 200240, China. dqwei@sjtu.edu.cn. 4 IASIA (International Association of Scientists in the Interdisciplinary Areas), 125 Boul. de Bromont, Quebec, QC, J2L 2K7, Canada. dqwei@sjtu.edu.cn.

Description:

The Food and Drug Administration (FDA) has recently authorized the two messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 for emergency use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 coronavirus disease. BNT162b2 and mRNA-1273 vaccines were developed by Pfizer-BioNTech and Moderna, respectively, in 2020. The United Kingdom, Bahrain, Canada, Mexico, United States, Singapore, Oman, Saudi Arabia, Kuwait, and European Union began their vaccination programs with the BNT162b2 vaccine, while the United States and Canada also started the mRNA-1273 vaccination program in mid December 2020. On 28th December 2020, studies reported severe allergic reactions in people who received the BNT162b2, and few people who received the mRNA-1273 vaccine. Authors of the letter thus attempt to explore possible causes of anaphylaxis following COVID-19 vaccination.

BookR: School of Health Core Facilities Booking

"SARS-Cov-2" Keyword-tagged Publications:

Search Publications

No results